Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis

• Market Cap: ₹4.09B
• Dividend Yield: N/A
• Average Volume (3M): 34.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -30.27%
• EPS Growth: -3470.06%
• Country: IN
• Employees: 1,686
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -7.85
• Shares Outstanding: 224,260,970
• 10 Day Avg. Volume: 25,321
• 30 Day Avg. Volume: 34,323
• PEG Ratio: <0.01
• Price to Book (P/B): 0.56
• Price to Sales (P/S): 0.32
• P/FCF Ratio: 4.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ₹17.00 ▼(-6.85% Downside)

Nectar Lifesciences Ltd. has a moderate overall stock score of 52. The most significant factor is the financial performance, which highlights challenges in profitability and cash flow consistency. Technical analysis shows strong bullish momentum, but overbought conditions suggest caution. Valuation is a concern due to the negative P/E ratio and lack of dividend yield.

Positive Factors

Market Reach

Strategic partnerships with distributors and retailers expand market reach, supporting long-term revenue growth and market penetration.

Export Potential

Strong export focus to health-conscious markets can drive sustainable revenue growth, leveraging global demand for natural products.

Product Diversification

Diversification across pharmaceuticals, nutraceuticals, and food products reduces dependency on a single segment, enhancing resilience.

Negative Factors

Revenue Decline

A significant decline in revenue growth indicates challenges in market demand or competition, impacting long-term financial stability.

Profitability Challenges

Sustained negative profit margins and declining revenue growth suggest issues in cost management and pricing power, affecting profitability.

Cash Flow Volatility

Volatile cash flow indicates potential instability in cash generation, which can hinder investment and operational flexibility.

Nectar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

How the Company Makes Money

Nectar Lifesciences Ltd. generates revenue through multiple key streams, primarily from the sale of honey and its by-products, which are distributed to both retail and wholesale markets. The company also profits from its pharmaceutical and nutraceutical products, which are marketed to health-conscious consumers and healthcare providers. Additionally, NECLIFE has established strategic partnerships with various distributors and retailers, enhancing its market reach and contributing to its overall earnings. The company’s focus on exports, particularly to markets that value natural health products, further amplifies its revenue potential.

Nectar Lifesciences Ltd. Financial Statement Overview

Summary

Nectar Lifesciences Ltd. faces challenges in maintaining consistent profitability and growth, as reflected in its income statement. The balance sheet indicates a stable capital structure but struggles with generating shareholder returns. Cash flow metrics show volatility, with some positive trends in recent periods. The company needs to address profitability and cash flow consistency to improve its financial health.

Income Statement

Nectar Lifesciences Ltd. has experienced significant volatility in its income statement metrics. The company reported a negative net profit margin and declining revenue growth rate in the latest period, indicating challenges in maintaining profitability and growth. The gross profit margin has also decreased over time, reflecting potential issues in cost management or pricing power. However, there were periods of positive EBIT and EBITDA margins, suggesting some operational efficiency during certain years.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the return on equity has been negative in recent periods, reflecting challenges in generating returns for shareholders. The equity ratio remains stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals fluctuating free cash flow growth, with a notable improvement in the latest period. The operating cash flow to net income ratio indicates some level of cash generation efficiency, although the free cash flow to net income ratio has been inconsistent. Overall, the cash flow position shows potential for improvement but remains volatile.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.92B	16.70B	16.84B	15.24B	16.69B	15.43B
Gross Profit	1.98B	3.02B	4.82B	579.91M	2.99B	2.58B
EBITDA	-1.26B	-245.66M	1.69B	994.97M	1.61B	612.51M
Net Income	-1.80B	-1.14B	49.95M	-241.83M	250.47M	-732.64M
Balance Sheet
Total Assets	0.00	20.47B	21.91B	21.89B	23.91B	23.88B
Cash, Cash Equivalents and Short-Term Investments	197.51M	272.63M	203.01M	178.94M	182.35M	259.58M
Total Debt	0.00	5.82B	6.36B	7.54B	8.60B	9.03B
Total Liabilities	-9.56B	10.91B	11.22B	11.25B	13.03B	13.26B
Stockholders Equity	9.56B	9.56B	10.69B	10.65B	10.88B	10.62B
Cash Flow
Free Cash Flow	0.00	1.26B	1.95B	1.04B	700.35M	-98.62M
Operating Cash Flow	0.00	1.69B	2.25B	1.34B	950.05M	213.79M
Investing Cash Flow	0.00	-419.30M	-170.25M	517.04M	166.44M	-286.24M
Financing Cash Flow	0.00	-1.28B	-2.05B	-1.86B	-1.19B	114.90M

Nectar Lifesciences Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 18.25 is below the 20-day moving average (MA) of 20.26, above the 50-day MA of 17.89, and below the 200-day MA of 18.88, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 43.17 is Neutral, neither overbought nor oversold. The STOCH value of 25.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.

Nectar Lifesciences Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹9.72B	13.81	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.40B	2.57	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.34B	43.00	―	―	24.20%	55.01%
ZIMLAB	63 Neutral	₹3.33B	50.60	―	―	-5.82%	-59.22%
MEDICAMEQ	57 Neutral	₹5.29B	47.58	―	0.26%	-9.16%	49.09%
NECLIFE	52 Neutral	₹4.09B	-1.13	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nectar Lifesciences Ltd. Corporate Events

Nectar Lifesciences Closes Trading Window Ahead of December Quarter Results

Nectar Lifesciences Ltd. has announced that, in compliance with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct, it will close its trading window for designated persons and their immediate relatives from January 1, 2026 until 48 hours after the declaration of its financial results for the period ended December 31, 2025. The move restricts insiders from trading in the company’s securities during the sensitive period around quarterly financial disclosures, reinforcing regulatory compliance and governance standards for investors and market participants.

Nectar Lifesciences to Divest Capsule Unit to Capnest Health Care in INR 19.9 Crore Slump Sale

Nectar Lifesciences Ltd. has entered into a Business Transfer Agreement with Capnest Health Care Private Limited to sell its Empty Hard Gelatin Capsule manufacturing, distribution and marketing unit located at Bhatoli Kalan, Baddi, Himachal Pradesh, on a slump sale and going-concern basis. The transaction, valued at INR 19.9 crore along with the takeover of related receivables, payables and other working capital adjustments, involves a business that contributed 1.28% of the company’s FY25 revenue and 2.25% of its net worth, and is expected to close on or before April 30, 2026; the buyer is unrelated to the promoter group, indicating a non-related-party divestment of a relatively small unit as the company fine-tunes its portfolio and capital allocation.

Nectar Lifesciences Announces Leadership Change and Share Buyback

Nectar Lifesciences Ltd. announced the appointment of Mr. Sushil Kapoor as an additional Director and Wholetime Director designated as Director (Finance), effective December 4, 2025. Additionally, the company has approved a buyback of equity shares amounting to INR 81 crore at a price of INR 27 per share, representing up to 13.38% of the total equity shares. This buyback is part of a strategic move to enhance shareholder value, with the promoters opting not to participate, and is managed by Master Capital Services Limited.

Nectar Lifesciences Announces Resignation of VP of Exports

Nectar Lifesciences Ltd. announced the resignation of Mr. Ashok Kumar from his position as Vice President (Exports), effective November 9, 2025. This change in senior management may impact the company’s export operations and strategic direction, potentially affecting its market positioning and stakeholder interests.